Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.
Voutsadakis IA.
Int J Gynecol Cancer. 2020 Oct;30(10):1619-1626. doi: 10.1136/ijgc-2019-000832. Epub 2019 Nov 27.
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, Chui H, Coleman RL, Fader AN, Gaillard S, Gourley C, Sood AK, Monk BJ, Moore KN, Ray-Coquard I, Shih IM, Westin SN, Wong KK, Gershenson DM.
Int J Gynecol Cancer. 2023 Sep 4;33(9):1331-1344. doi: 10.1136/ijgc-2023-004610.
Low-grade serous ovarian carcinoma: A comprehensive literature review.
Goulding EA, Simcock B, McLachlan J, van der Griend R, Sykes P.
Aust N Z J Obstet Gynaecol. 2020 Feb;60(1):27-33. doi: 10.1111/ajo.13105. Epub 2019 Dec 17.
Ovarian low-grade serous carcinoma: a comprehensive update.
Diaz-Padilla I, Malpica AL, Minig L, Chiva LM, Gershenson DM, Gonzalez-Martin A.
Gynecol Oncol. 2012 Aug;126(2):279-85. doi: 10.1016/j.ygyno.2012.04.029. Epub 2012 Apr 30.
A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma.
Voutsadakis IA.
Eur J Obstet Gynecol Reprod Biol. 2021 Jan;256:172-178. doi: 10.1016/j.ejogrb.2020.11.021. Epub 2020 Nov 12.
Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Goldberg RM, Kim SR, Fazelzad R, Li X, Brown TJ, May T.
Gynecol Oncol. 2022 Jan;164(1):212-220. doi: 10.1016/j.ygyno.2021.10.080. Epub 2021 Oct 28.
CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.
Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C, Athineos D, Mason S, Stevenson D, Blyth K, Strathdee D, Balkwill FR, Vousden K, Lockley M, McNeish IA.
Cancer Res. 2016 Oct 15;76(20):6118-6129. doi: 10.1158/0008-5472.CAN-16-1272. Epub 2016 Aug 16.
Low grade serous ovarian carcinoma: identifying variations in practice patterns.
Siemon J, Gershenson DM, Slomovitz B, Schlumbrecht M.
Int J Gynecol Cancer. 2019 Jan;29(1):174-180. doi: 10.1136/ijgc-2018-000018.
Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, Cecere SC, Gargiulo P, Pignata S.
Cancer Treat Rev. 2015 Feb;41(2):136-43. doi: 10.1016/j.ctrv.2014.12.003. Epub 2014 Dec 23.
Micropapillary pattern in serous borderline ovarian tumor and the risk of extraovarian localization of low-grade serous carcinoma ('invasive implants'): A systematic review and meta-analysis.
Scaglione G, Travaglino A, Raffone A, Santoro A, Arciuolo D, Fulgione C, D'Alessandris N, Pannone G, Urtueta BP, Narducci N, Addante F, Casarin J, Ronchi S, Di Lauro E, La Rosa S, Maccio L, Inzani F, Zannoni GF.
Pathol Res Pract. 2024 Dec;264:155714. doi: 10.1016/j.prp.2024.155714. Epub 2024 Nov 6.
